Stifel Financial Corp Atara Biotherapeutics, Inc. Transaction History

Stifel Financial Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$1.5 - $3.04 $24,018 - $48,676	-16,012 Reduced 56.2%	12,480 $20,000
Q1 2023 May 12, 2023	BUY	$2.8 - $5.46 $2,049 - $3,996	732 Added 2.64%	28,492 $82,000
Q4 2022 Feb 13, 2023	SELL	$2.85 - $5.18 $2,736 - $4,972	-960 Reduced 3.34%	27,760 $91,000
Q3 2022 Nov 14, 2022	BUY	$2.85 - $8.73 $51,832 - $158,772	18,187 Added 172.67%	28,720 $109,000
Q2 2022 Aug 15, 2022	BUY	$4.69 - $9.84 $1,163 - $2,440	248 Added 2.41%	10,533 $82,000
Q1 2022 May 13, 2022	SELL	$8.44 - $16.89 $2,405 - $4,813	-285 Reduced 2.7%	10,285 $96,000
Q4 2021 Feb 14, 2022	SELL	$14.7 - $19.89 $4,939 - $6,683	-336 Reduced 3.08%	10,570 $167,000
Q3 2021 Nov 15, 2021	BUY	$11.99 - $17.9 $4,244 - $6,336	354 Added 3.35%	10,906 $195,000
Q2 2021 Aug 13, 2021	SELL	$12.89 - $16.58 $3,274 - $4,211	-254 Reduced 2.35%	10,552 $164,000
Q1 2021 May 14, 2021	BUY	$14.0 - $20.72 $151,284 - $223,900	10,806 New	10,806 $155,000

2.89M

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $1.08B
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Stifel Financial Corp with notifications on news.